Loading...
•
Dec 31, 2020
CervoMed Q4 2020 Earnings Report
Reported financial results for 2020 and provided a business update.
Key Takeaways
Diffusion Pharmaceuticals reported its 2020 financial results, highlighting a transformational year with a strengthened management team, advancement of its TSC development, and enhanced financial stability through multiple offerings.
Strengthened management team with key appointments.
Advanced development of trans sodium crocetinate (TSC) with a Phase 1b trial in COVID-19 patients.
Initiated three oxygenation studies to explore the relationship between TSC exposure and oxygenation levels.
Enhanced financial stability with $18.5 million in cash and cash equivalents as of December 31, 2020, and additional proceeds received in Q1 2021.
Forward Guidance
The company intends to undertake a prospective exploration of the relationship between the level of TSC exposure (dose) and response (change in oxygenation) by conducting three short-term clinical trials in the United States during 2021.
Positive Outlook
- Evaluate the effects of TSC on peripheral tissue oxygenation using a transcutaneous oxygen monitoring (“TCOM”) device.
- Evaluate the effects of TSC on maximal oxygen consumption (VO2), and partial pressure of blood oxygen (PaO2), in normal healthy volunteers exposed to conditions that induce hypoxia.
- Evaluate the effects of TSC on the diffusion of carbon monoxide through the lungs (“DLCO”) in patients with previously diagnosed interstitial lung disease who have a baseline DLCO test result that is abnormal.
- Outcomes from one or each of these Oxygenation Trials will inform the company’s go-forward TSC clinical development path, focusing on the demonstration of clinical and therapeutic benefits of TSC in relevant patient populations across the hypoxia continuum.
- Assuming success in one or more of the three Oxygenation Trials, the Company expects to identify and announce the specific, hypoxia-related indication it will target, in the fourth quarter of 2021.
Challenges Ahead
- The Company’s ability to design, initiate, enroll, execute, and complete its ongoing and planned studies evaluating TSC
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...